TRIPLE NEGATIVE BREAST CANCER

This study tests a new vaccine called Modi-1 in people with advanced breast, head and neck, ovarian, or kidney cancer. The vaccine is designed to help the immune system recognize and attack cancer cells. Some participants will receive the vaccine alone, while others will get it t…

This early-phase trial tests a personalized vaccine made from a patient's own tumor DNA. The goal is to train the immune system to recognize and attack any remaining cancer cells after standard chemotherapy and surgery. The study enrolls 16 adults with high-risk triple negative b…

This early-phase study is testing an experimental drug called DR-0202 in about 96 people with advanced solid tumors (like breast, lung, or pancreatic cancer) that have not responded to at least two prior treatments. The main goal is to check the drug's safety and find the best do…

This study is for people with metastatic breast cancer (cancer that has spread). It aims to see if choosing treatments based on specific tumor markers (biomarkers) can help control the disease longer. About 700 participants will receive standard therapies matched to their biomark…

This study tests whether matching treatments to the genetic fingerprint of each person's triple-negative breast cancer can shrink tumors or slow the disease. It is for women whose cancer has spread or returned and has not responded to standard therapies. Researchers will assign d…

This early-phase trial tests a new drug, ASTX660, combined with the immunotherapy pembrolizumab in people with advanced solid tumours, including cervical and triple-negative breast cancer. The goal is to see if blocking certain proteins can make cancer cells die in a way that tri…

This study tests a new drug called LY4175408 in people with advanced lung, endometrial, or breast cancer that has spread. The drug is designed to target and kill cancer cells while sparing healthy ones. The goal is to check safety, how the drug moves through the body, and whether…

This study tests whether adding the drug serplulimab to standard chemotherapy before surgery can improve outcomes for people with triple-negative breast cancer. About 46 women aged 18-70 with early-stage disease will receive the combination. The main goal is to see if the cancer …

This study is testing whether combining an immunotherapy drug (atezolizumab), an immune-boosting agent (BDB001), and targeted radiation can help control advanced solid tumors. It includes people with pancreatic cancer, lung cancer, melanoma, bladder cancer, triple-negative breast…

This early-stage study tests a new treatment for triple negative breast cancer that has come back or not responded to other therapies. The treatment uses a patient's own immune cells, which are modified in a lab to better recognize and attack cancer cells. The main goal is to che…

This early-phase study tests a new treatment called PeptiCRAd-1, a virus-based cancer vaccine, combined with the immunotherapy drug pembrolizumab. The goal is to see if this combination is safe and can boost the immune system to fight several types of solid tumors, including mela…

This early-phase study tests an experimental pill called ATX-295 in people with advanced solid tumors, including ovarian and breast cancers that have not responded to standard treatments. The drug works by blocking a protein (KIF18A) that cancer cells need to divide. The main goa…

This study is testing a specific chemotherapy combination (epirubicin + cyclophosphamide followed by docetaxel + carboplatin) in Nigerian women with triple-negative breast cancer. The main goal is to see how many women have no cancer cells left in their breast or lymph nodes afte…

This early-phase study tests a new drug called BL-B01D1 in people with advanced lung cancer or other solid tumors that have spread or cannot be removed. The main goals are to check the drug's safety and find the best dose. About 470 adults will take part to see if the drug can he…

This study tests a new drug called CTX-8371 in people with advanced cancers that have not responded to standard treatments. The main goal is to check the drug's safety and find the best dose. About 85 adults with certain types of lung, breast, lymphoma, head and neck, or skin can…

This study tests whether adding durvalumab to datopotamab deruxtecan helps people with a type of advanced breast cancer called PDL1-negative triple-negative breast cancer. About 140 women will be randomly assigned to get either the drug combination or the single drug alone. The g…

This early-phase study tests two drugs, palbociclib and avelumab, together for people with a specific type of advanced breast cancer (AR+ triple-negative). The main goals are to find the safest doses and see if the combination can shrink tumors. About 45 participants with advance…

This study tests a new drug called Rina-S in people with advanced solid tumors that have spread or can't be removed by surgery. The goal is to see if Rina-S is safe and how well it works against cancers like ovarian, lung, and breast cancer. About 764 participants will receive th…

This study tests whether adding tetrathiomolybdate (TM) to standard capecitabine can lower the chance of breast cancer returning in patients with high-risk triple-negative breast cancer. About 204 participants who have completed initial treatment and surgery will receive either T…

This study tests an experimental drug called AZD6750, designed to help the immune system fight cancer. It is for adults with advanced solid tumors (like melanoma, lung, or breast cancer) that have spread. The trial will first find the safest dose, then test if it works alone or w…

This study tests whether combining two drugs, sacituzumab govitecan and atezolizumab, can clear leftover cancer cells in the breast or lymph nodes after initial treatment. It includes 40 people with triple negative breast cancer who still have signs of cancer in their blood. The …

This study tests whether a new drug combination (sacituzumab govitecan plus pembrolizumab) works better than standard treatments for people with triple negative breast cancer that still remains after surgery and pre-surgery therapy. About 1,514 adults will take part. The goal is …

This study tests whether early PET scans can help doctors adjust chemotherapy and immunotherapy for people with stage 2 or 3 triple negative breast cancer. About 30 participants will receive four cycles of chemo plus the drug pembrolizumab. A PET scan after the first cycle will s…

This study is for people with a type of breast cancer called triple-negative that has stopped responding to standard immunotherapy. Researchers are testing whether adding a mix of other drugs can make the cancer respond again. The trial will enroll 80 participants and measure how…

This study tests two different chemotherapy combinations given before surgery for people with triple-negative breast cancer. The goal is to see which combo works better at shrinking tumors, making surgery easier and more effective. About 520 participants will be randomly assigned…

This study tests a combination of three drugs (atezolizumab, vinorelbine, and cyclophosphamide) in people with advanced triple-negative breast cancer that has come back after prior immunotherapy. The goal is to see if this combo can shrink tumors and help control the disease. Abo…

This study tests whether adding a new drug (MK-2870) to standard immunotherapy (pembrolizumab) can prevent breast cancer from returning in people with triple-negative breast cancer who still had cancer after initial treatment and surgery. About 1,530 participants will receive eit…

This study tests two different chemotherapy drug combinations in people with advanced triple-negative breast cancer, a fast-growing type. The goal is to see which combo works better at controlling the disease and extending life. Participants will receive either nab-paclitaxel plu…

This study tests a new oral drug, VLS-1488, in people with advanced solid tumors that have not responded to other treatments. The goal is to find a safe dose and see if it can shrink tumors or slow cancer growth. About 200 adults with specific cancers like ovarian, lung, or breas…

This study tests a new drug called PC14586 (rezatapopt) in people with advanced or spreading solid tumors that have a specific change in the TP53 gene (Y220C mutation). The goal is to see if the drug is safe and works against these cancers. About 300 adults (and some teens after …

This study tests whether a structured nutrition and exercise program can improve the chance of having no cancer left after chemo-immunotherapy in women with triple-negative breast cancer. Participants will be randomly assigned to the lifestyle program or usual care. The goal is t…

This study tests whether adding the arthritis drug tocilizumab to standard chemotherapy helps shrink tumors or delay cancer growth in people with metastatic triple-negative or ER-low breast cancer. The trial includes both Black and non-Black participants to see if the drug works …

This study is for people with early-stage triple-negative breast cancer who are scheduled for surgery. Before surgery, they will receive two drugs: lenvatinib (taken daily for 7 days) and one dose of pembrolizumab (given by IV). The goal is to see if this short treatment can incr…

This early-phase trial tests an investigational vaccine made from a patient's own immune cells, designed to target two cancer-related proteins (HER2 and HER3). It is given directly into the tumor along with standard chemotherapy before surgery. The study includes 30 adults with e…

This early-phase trial tests a new drug called bulumtatug furvedotin (BFv) in people with triple-negative breast cancer that has returned or spread and who have already tried certain other treatments. The study aims to see if BFv can shrink tumors or stop them from growing. About…

This study looks at whether some women with early-stage triple-negative breast cancer can receive less chemotherapy. It includes two groups: one gets a combination of immunotherapy (pembrolizumab) and a lower dose of chemo, and the other gets no treatment after surgery, just regu…

This early-stage trial tests a new drug, ONM-501, injected directly into tumors, either alone or with another drug (cemiplimab), for people with advanced solid tumors or lymphomas that have not responded to other treatments. The study aims to find the safest dose and check for si…

This study tests whether adding the immunotherapy drug pembrolizumab, with or without the targeted drug olaparib, to standard radiation therapy is safe and effective for people with metastatic triple-negative or hormone-receptor-positive breast cancer. About 34 participants will …

This study tests two new drug combinations for people with advanced triple-negative breast cancer that has come back or spread. About 80 adults aged 18-75 who have not had prior treatment for advanced disease will receive either JS207 plus 9MW2821 or JS207 plus albumin paclitaxel…

This early-phase trial tests a new drug called ZM008, alone and with another drug (toripalimab), in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find a safe dose and check for side effects. About 100 adults with canc…

This early-phase trial tests an experimental drug called MOv18 IgE in people with advanced ovarian, endometrial, or triple-negative breast cancers that have high levels of a protein called folate receptor alpha. The study has two parts: first, finding a safe dose, and then checki…

This study tests whether a combination of three drugs (camrelizumab, apatinib, and eribulin) works better than standard chemotherapy for people with advanced triple-negative breast cancer. The trial involves 246 women aged 18 to 70 whose cancer has spread. The goal is to see if t…

This study tests a different dose and schedule of the drug sacituzumab govitecan in people with advanced triple-negative breast cancer (TNBC). The goal is to see if this new approach is safe and works better at shrinking tumors or slowing cancer growth. About 100 adults with TNBC…

This study looks at whether taking vitamin D supplements during standard chemotherapy can help shrink tumors more effectively in people with triple negative breast cancer who are low in vitamin D. About 50 participants will either receive vitamin D plus chemotherapy or just chemo…

This study tests a new treatment using specially engineered immune cells (CAR-NK cells) to fight advanced breast cancer. About 60 adults with HER2-positive or triple-negative breast cancer that has spread or cannot be removed will receive cells tailored to their tumor's markers. …

This study tests a new drug called LY4052031 in people with advanced or spreading solid tumors, including bladder, breast, lung, and other cancers. The goal is to see if the drug is safe and works against these cancers. About 420 participants will take part, and the study will la…

This study tests whether a medicine called pegfilgrastim can help prevent a serious infection (febrile neutropenia) in people with triple-negative breast cancer who are getting a specific type of chemotherapy. About 40 adults will receive the medicine after each chemo cycle. The …

This study tests two drug combinations in people with early-stage, low-risk triple-negative breast cancer. Participants receive either sacituzumab govitecan alone or with pembrolizumab before surgery. The goal is to see which approach leads to higher rates of complete tumor disap…

This early-phase trial tests a new drug called JANX008 in adults with advanced solid tumors (like lung, kidney, breast, or colorectal cancer) that have stopped responding to standard treatments. The main goals are to check safety, find the right dose, and see if the drug can shri…

This phase 3 trial tests whether adding the antibiotic moxifloxacin to standard chemotherapy can slow the growth of metastatic triple-negative breast cancer. About 228 adults with this aggressive cancer who have not yet received treatment for their advanced disease will take eith…

This study tests a new drug called SKB264 against standard chemotherapy as the first treatment for people with advanced triple-negative breast cancer that cannot be removed by surgery or has spread. The trial includes 524 adults whose tumors do not express PD-L1, or who have alre…

This study tests a new treatment called NECVAX-NEO1 added to standard therapy for people with triple-negative breast cancer. The goal is to see if it is safe and helps control the disease before and after surgery. About 12 participants will receive the treatment alongside chemoth…

This early-stage study tests a new drug called azirkitug, alone or with other medicines, in people with advanced solid tumors like lung, head/neck, and other cancers. The goal is to find safe doses and check side effects. About 694 adults will take part at sites worldwide.

This early-phase study tests a new drug (177Lu-DFC413) that delivers radiation directly to cancer cells in adults with advanced solid tumors like pancreatic, lung, breast, colorectal, and soft tissue cancers. The main goals are to check safety, find the right dose, and see if it …

This early-phase study tests an experimental pill, NKT3964, designed to break down a protein (CDK2) that helps cancer cells grow. About 150 adults with advanced or metastatic solid tumors (including ovarian, endometrial, breast, gastric, and lung cancers) that have stopped respon…

This study tests whether adding pembrolizumab (Keytruda) to sacituzumab govitecan (Trodelvy) helps people with a specific type of advanced breast cancer (triple-negative, PD-L1-negative) live longer without the disease getting worse. About 110 participants will be randomly assign…

This study tests a new treatment called A2B395 for adults with advanced solid tumors (like colorectal, lung, breast, and kidney cancers) that have not responded to standard therapy. The treatment uses specially engineered immune cells designed to kill cancer cells while protectin…

This study tests a new drug called JSKN016 against standard treatments chosen by the doctor for people with advanced triple-negative breast cancer that has worsened after at least two prior therapies. About 364 adults aged 18 to 75 will take part. The goal is to see if JSKN016 he…

This study tests whether giving high-precision radiation (SBRT) to all visible tumors can delay cancer worsening in people with 1 to 5 metastases from breast or lung cancer. About 145 participants will be randomly assigned to receive either standard care alone or standard care pl…

This study is for people with advanced triple-negative breast cancer whose disease is under control after initial immunotherapy. It compares giving the same dose of immunotherapy less often versus the standard schedule. The goal is to see if the longer interval can keep the cance…

This study tests whether adding the drug VEGFR BP102 to standard chemotherapy (nab-paclitaxel) helps people with a specific subtype of advanced triple-negative breast cancer (called BLIS) live longer without their cancer growing. About 134 adults who have not had prior treatment …

This early-phase study tests a new radioactive drug, [177Lu]Lu-NNS309, in adults with advanced pancreatic, lung, breast, or colorectal cancers that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug can shrink t…

This study tests a drug called sacituzumab govitecan, given before surgery, in people with localized triple-negative breast cancer. The goal is to see if it can eliminate all cancer in the breast and lymph nodes. Some participants may also receive pembrolizumab. The study involve…

This early-phase study tests a new drug called XMT-1660 in people with advanced solid tumors, including triple-negative breast, ovarian, and endometrial cancers. The main goals are to find the safest dose and check for side effects. About 319 participants will receive the drug to…

This early-phase study tests an experimental oral drug called CID-078 in 220 adults with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if the drug is safe and can shrink tumors. It is a first-in-human trial, so the main focus is on …

This study tests a new cancer pill (PF-08032562) in people with advanced breast or colorectal cancer that has spread. The goal is to find the safest dose and see how well it works alone or with other treatments. About 260 adults will take the pill daily in 28-day cycles, with som…

This early-stage trial tests a treatment where a patient's own immune cells are modified in a lab to better recognize and attack cancer cells that have a marker called NY-ESO-1. The study includes people with advanced cancers like sarcoma, melanoma, breast, lung, bladder, and ova…

This early-stage study tests a new drug called IDE034 in 150 adults with advanced solid tumors (like lung, ovarian, or colon cancer) that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors…

This study tests an experimental drug called LBL-024, given alone or with chemotherapy, in people whose triple negative breast cancer has come back or spread. The goal is to see if the drug can shrink tumors and slow the disease. About 220 adults with this aggressive cancer type …

This study tests a 12-18 week combination of chemotherapy (carboplatin and paclitaxel) and immunotherapy (pembrolizumab) for people with triple-negative breast cancer who cannot take standard anthracycline-based chemo because of heart conditions or high risk of heart damage. The …

This study tests a new drug called APL-5125 in about 100 adults with advanced solid tumors, including colorectal, pancreatic, and ovarian cancers. The goal is to check safety and see if the drug can shrink tumors. Participants must have tried standard treatments first.

This study tests whether adding an experimental drug (INBRX-106) to an approved immunotherapy (pembrolizumab) can shrink tumors in people with stage II or III triple-negative breast cancer before they start standard chemotherapy. About 12 adults with measurable tumors will receiv…

This phase 2 trial tests whether injecting the drug INT230-6 into the tumor before standard chemotherapy and immunotherapy can increase the chance of eliminating all cancer in the breast and lymph nodes before surgery. About 61 people with early triple-negative breast cancer will…

This study tests whether adding an antivascular drug to standard chemotherapy helps prevent breast cancer from returning in people with a specific, high-risk type of triple-negative breast cancer. About 764 women with stage II to III cancer will receive either the combination or …

This study tests whether using a tumor's genetic profile to customize radiation doses can better control triple negative breast cancer after lumpectomy. About 86 participants will receive radiation tailored to their individual risk, with the goal of preventing cancer from returni…

This study tests whether adding a type of radiation (stereotactic radiosurgery) and an immunotherapy drug (zimberelimab) to a standard chemotherapy (sacituzumab govitecan) is safe and works better than the chemotherapy alone for people with triple negative breast cancer that has …

This study tests a combination of chemotherapy drugs (albumin-bound paclitaxel and carboplatin) plus an immunotherapy drug (Camrelizumab) given before surgery to people with early-stage triple-negative breast cancer. The goal is to see if this approach leads to no cancer remainin…

This study is testing whether a combination of three drugs—pembrolizumab, carboplatin, and paclitaxel—can effectively shrink tumors in people with early-stage triple-negative breast cancer before they have surgery. The goal is to see if this approach can completely eliminate canc…

This study tests if a special mammogram with contrast dye can predict whether breast cancer has been completely eliminated by chemotherapy, just as well as an MRI does. About 30 women with locally advanced breast cancer will get 1-2 of these mammograms during or after chemo, befo…

This study tests whether a new type of PET scan (68Ga-FAPI-46) can predict if triple-negative breast cancer will completely respond to chemotherapy plus immunotherapy before surgery. About 60 women with early-stage, high-risk breast cancer will receive the scan before starting tr…

This study looks at 42 women with triple negative breast cancer, an aggressive type that lacks targeted treatments. Participants will receive standard chemotherapy, and researchers will measure tiny molecules in the blood (microRNA and tumor DNA) to see if changes can signal earl…

This study looks at whether a blood test can find tiny bits of tumor DNA (ctDNA) in people with early-stage triple-negative breast cancer. Researchers will collect blood samples before and during treatment to see if the test can help predict cancer coming back. About 77 participa…

This study is for people with triple-negative breast cancer who still have cancer cells after standard chemotherapy. Researchers will use a simple blood test (liquid biopsy) to look for tumor DNA before and during treatment with the drug capecitabine. The goal is to learn whether…

This study looks at whether a blood test that measures circulating tumor DNA (ctDNA) can help predict how well breast cancer responds to chemotherapy before surgery. Researchers will take blood samples from 125 women with stage II or III breast cancer before, during, and after tr…

This study takes small tumor samples from people with triple-negative breast cancer and grows them in the lab as 3D mini-tumors called organoids. Researchers will test different drugs on these organoids to see which ones work best and look for biological markers that predict trea…

This study is testing whether routine brain MRI scans can detect breast cancer that has spread to the brain in patients with certain types of advanced breast cancer. Researchers will follow 214 participants over time to see if early detection improves quality of life and reduces …

This study looks at whether regular blood tests (ctDNA monitoring) and special PET scans can find triple negative breast cancer returning earlier in women at high risk. About 450 women who finished treatment for early-stage cancer will be monitored. If the blood test detects sign…

This study looks at whether it is possible and acceptable to take multiple tissue samples (biopsies) from different tumor sites over time in people with metastatic breast cancer. The goal is to understand how the cancer changes and becomes resistant to treatment. Researchers will…

This study looks at whether a special PET scan can find triple negative breast cancer that has spread. Researchers will compare this new scan to the standard one in 30 women. If it works well, it could lead to a new type of treatment for this hard-to-treat cancer.

This study is testing whether a special whole-body MRI (DWB-MRI) can detect the return or spread of breast cancer earlier than standard methods. It involves 145 people with high-risk breast cancer types (HER2+ or triple-negative) who have had surgery. The goal is to see if earlie…

This study looks at whether regular brain MRIs can find cancer that has spread to the brain in people with stage IV breast cancer who have no brain symptoms. About 170 participants will get a screening brain MRI at the start and again at 6 months or when their cancer first progre…

This study is for 500 adults with breast cancer who are about to start treatment like chemotherapy or immunotherapy before surgery. Researchers will collect tumor tissue, blood, and sometimes MRI scans and stool samples during treatment. The goal is to learn why some cancers shri…

This study looks at how near-complete estrogen deprivation (NCED) therapy, used to treat breast cancer, affects heart function. Researchers will use heart scans to measure blood flow in 90 women aged 55 or younger who are premenopausal at diagnosis. The goal is to understand if t…

This study tests whether a special PET/MRI scan can help doctors see how well immunotherapy is working in people with triple negative breast cancer. About 20 patients will get the scan before and during their standard treatment. The results will not change their care but may help…

This study looks at bacteria living in breast tumors to see if they can help predict how well chemotherapy and immunotherapy work in people with early-stage triple negative breast cancer. Researchers will collect tissue samples before and after treatment from 30 participants. The…

This study is gathering tumor, blood, and plasma samples from over 1,000 people with certain cancers (ovarian, triple-negative breast, head and neck, cervical, vulva, and sarcoma). The goal is to find new biomarkers that link a tumor's genetic changes and the body's immune respon…

This study looks at 115 people with triple-negative breast cancer who are getting chemotherapy plus immunotherapy before surgery. Researchers want to see which imaging method—ultrasound, mammogram, MRI, or PET-CT—best predicts whether the cancer is completely gone after treatment…